RxDoctor Payments Data

Michael Brown, MD

Family Medicine · Lewisburg, PANPI 1386614063

Payments from drug & device makers

$2,205in general payments, 2019–2025

Across 130 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$245
  • AbbVie$229
  • GSK$217
  • Lilly USA, LLC$210
  • Exact Sciences$136
  • Novo Nordisk$131
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,205 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$116,066
Medicare patients
339
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$189,501
JardianceEmpagliflozin138$148,961
OzempicSemaglutide96$91,039
Xeljanz XrTofacitinib Citrate12$68,293
XareltoRivaroxaban25$32,250
TrulicityDulaglutide24$26,316
JanuviaSitagliptin Phosphate23$18,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$8,786
FarxigaDapagliflozin Propanediol11$6,426
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,404
MyrbetriqMirabegron11$6,164
Fentanyl39$5,755
Atorvastatin Calcium382$5,610
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,984
Metoprolol Succinate229$4,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$105$189,501212 claims
Boehringer IngelheimJardiance$102$148,961138 claims
Novo NordiskOzempic$131$91,03996 claims
Johnson & JohnsonXarelto$79$32,25025 claims
Lilly USA, LLCTrulicity$210$26,31624 claims
MerckJanuvia$66$18,46323 claims
AstraZenecaFarxiga$245$6,42611 claims
Sanofi-aventis U.S. LLCLantus$18$2,82913 claims
AbbVieSynthroid$229$1,32921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lewisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →